DÄ internationalArchive50/2006Adjuvant Treatment with Trastuzumab in Patients with Breast Cancer

Review article

Adjuvant Treatment with Trastuzumab in Patients with Breast Cancer

Dtsch Arztebl 2006; 103(50): A-3406

Untch, M; Jackisch, C; Thomssen, C; Nitz, U; Minckwitz, G v; Kaufmann, M

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland Hrsg. in Zusammenarbeit mit dem Robert Koch Institut: Krebs in Deutschland. Häufigkeiten und Trends. Saarbrücken 2006, 52.
2. Goldhirsch A, Glick JH, Gelber RD et al.: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16: 1569–83. MEDLINE
3. Slamon DJ, Godolphin W, Jones LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989: 244: 707–12. MEDLINE
4. National Institute for Health and Clinical Excellence (NICE): Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. www.nice.org.uk
5. Romond EH, Perez EA, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–84. MEDLINE
6. Piccart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353; 1659–72. MEDLINE
7. Smith I, Procter M, Gelber RD et al.: Improved survival with trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. Lancet 2006 angenommen.
8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al.: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809–20. MEDLINE
9. Buzdar AU, Ibrahim NK, Francis D et al.: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 1–10. MEDLINE
10. Tan-Chiu E, Yothers G, Romond E et al.: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23: 7811–9. MEDLINE
11. Arbeitsgemeinschaft Gynäkologische Onkologie e.V. (AGO) Organkommission Mammakarzinom (2006): Adjuvante Therapie mit Trastuzumab. www.ago-online.org